209 related articles for article (PubMed ID: 35782601)
1. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.
Lee SH; Kim HY; Cho TJ; Kim H; Ko JM
Mol Genet Metab Rep; 2022 Jun; 31():100869. PubMed ID: 35782601
[TBL] [Abstract][Full Text] [Related]
2. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
[TBL] [Abstract][Full Text] [Related]
3. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis.
Lee CL; Chuang CK; Syu YM; Chiu HC; Tu YR; Lo YT; Chang YH; Lin HY; Lin SP
J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013287
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study.
Ficicioglu C; Matalon DR; Luongo N; Menello C; Kornafel T; Degnan AJ
Orphanet J Rare Dis; 2020 Nov; 15(1):336. PubMed ID: 33256811
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes.
Politei J; Porras-Hurtado GL; Guelbert N; Fainboim A; Horovitz DDG; Satizábal JM
JIMD Rep; 2021 Mar; 58(1):104-113. PubMed ID: 33728253
[TBL] [Abstract][Full Text] [Related]
7. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa.
Mitchell JJ; Burton BK; Bober MB; Campeau PM; Cohen S; Dosenovic S; Ellaway C; Bhattacharya K; Guffon N; Hinds D; Lail A; Lin SP; Magner M; Raiman J; Schwartz-Sagi L; Stepien KM
Mol Genet Metab; 2022; 137(1-2):164-172. PubMed ID: 36087504
[TBL] [Abstract][Full Text] [Related]
8. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
9. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
10. A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.
Nakamura-Utsunomiya A; Nakamae T; Kagawa R; Karakawa S; Sakata S; Sakura F; Tani C; Matsubara Y; Ishino T; Tajima G; Okada S
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32024277
[TBL] [Abstract][Full Text] [Related]
11. Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program.
Pintos-Morell G; Blasco-Alonso J; Couce ML; Gutiérrez-Solana LG; Guillén-Navarro E; O'Callaghan M; Del Toro M
Mol Genet Metab Rep; 2018 Jun; 15():116-120. PubMed ID: 30023300
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience.
Quijada-Fraile P; Arranz Canales E; Martín-Hernández E; Ballesta-Martínez MJ; Guillén-Navarro E; Pintos-Morell G; Moltó-Abad M; Moreno-Martínez D; García Morillo S; Blasco-Alonso J; Couce ML; Gil Sánchez R; Cortès-Saladelafont E; López Rodríguez MA; García-Silva MT; Morales Conejo M
Orphanet J Rare Dis; 2021 Nov; 16(1):464. PubMed ID: 34732228
[TBL] [Abstract][Full Text] [Related]
13. Elosulfase alfa: first global approval.
Sanford M; Lo JH
Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 Jun; 14(1):137. PubMed ID: 31196221
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.
Tomatsu S; Sawamoto K; Shimada T; Bober MB; Kubaski F; Yasuda E; Mason RW; Khan S; Alméciga-Díaz CJ; Barrera LA; Mackenzie WG; Orii T
Expert Opin Orphan Drugs; 2015 Nov; 3(11):1279-1290. PubMed ID: 26973801
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy.
Aguilar Delgado C; Hammerschmidt T; Faverzini JL; Lopes F; Giugliani R; Baldo G; Vargas CR
Arch Biochem Biophys; 2023 Mar; 737():109541. PubMed ID: 36754222
[TBL] [Abstract][Full Text] [Related]
18. Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome (case report).
Hiramatsu M; Nakamura K
Mol Genet Metab Rep; 2017 Dec; 13():76-79. PubMed ID: 28971020
[TBL] [Abstract][Full Text] [Related]
19. Integrated Management of an Adult Patient with Mucopolysaccharidosis type IVA: A Case Report with a Six-Year Follow-up.
Vergatti A; Abate V; Della Monica M; De Filippo G; Rendina D; Barbato A
Eur J Case Rep Intern Med; 2024; 11(1):004113. PubMed ID: 38223275
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
